SCNI (Scinai Immunotherapeutics) Current Accrued Expense: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNI Scinai Immunotherapeutics Ltd SCNI
20 GF Score
Price $1.95
! 2 Warning Signs
View Full Analysis

What is Scinai Immunotherapeutics Current Accrued Expense?

Scinai Immunotherapeutics SCNI -16.67% 20 Current Accrued Expense is $0.00 Mil as of Jun. 2026. GuruFocus rates SCNI with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Scinai Immunotherapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.00 Mil.

Scinai Immunotherapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($0.76 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Scinai Immunotherapeutics's annual Current Accrued Expense declined from Dec. 2023 ($0.85 Mil) to Dec. 2024 ($0.78 Mil) and declined from Dec. 2024 ($0.78 Mil) to Dec. 2025 ($0.76 Mil).

Scinai Immunotherapeutics Current Accrued Expense Related Terms

Scinai Immunotherapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Scinai Immunotherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinai Immunotherapeutics Current Accrued Expense Chart

Scinai Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 1.24 0.85 0.78 0.76

Scinai Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.76 0.00 0.00
SCNI
20GF Score
Scinai Immunotherapeutics Ltd SCNI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinai Immunotherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.00 Mil mean?
Scinai Immunotherapeutics (SCNI) has a Current Accrued Expense of $0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scinai Immunotherapeutics and its competitors.
Is Scinai Immunotherapeutics' Current Accrued Expense too high?
Scinai Immunotherapeutics' current Current Accrued Expense is $0.00 Mil. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' Current Accrued Expense compare to BBLG and PTIX?
Scinai Immunotherapeutics' Current Accrued Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Scinai Immunotherapeutics and its competitors. Scinai Immunotherapeutics's current Current Accrued Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (SCNI) has a current Current Accrued Expense of $0.00 Mil. The current Current Accrued Expense is $0.00 Mil. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Scinai Immunotherapeutics (SCNI), the current Current Accrued Expense is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scinai Immunotherapeutics Business Description

Address Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score

Get the complete analysis for SCNI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.95
Price